Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

– Agreement supports commitment to patient access, affordability and innovation – TOKYO, Aug. 31, 2026 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that it has reached an agreement with the U.S. government that reflects our commitment to patient access, affordability and innovation, while reinforcing Astellas' longstanding commitment to the U.S. healthcare system. Under the agreement, Astellas will take the following actions: Lower the prices of medicines in Medicaid and establish pricing for future medicines aligned with other developed nations that reflect international market conditions, innovation, and patient value.

The agreements provide for all state Medicaid programs to pay prices for prescription drugs that match the lowest prices paid by other developed nations, the White House said

At the start of the quarter, compared to its MSCI All Country World Ex-United States benchmark, the Carillon ClariVest International Stock Fund was most overweight to the information technology and health care sectors and most underweight to the consumer discretionary and energy sectors. Top securities include SK hynix, Samsung Electronics, Yageo Corporation, Taiwan Semiconductor and Kioxia Holdings. Bottom securities include Astellas Pharma, TotalEnergies, Kinross Gold, Deutsche Telekom and Alibaba Group.

The portfolio outperformed the MSCI EAFE benchmark in the second quarter of 2026. Contributors include Infineon Technologies, Tokyo Electron and Recruit Holdings. Detractors include Murata Manufacturing, SoftBank Group and Astellas Pharma.